We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Plasma Amyloid-β 42/40 Assays Compared in Alzheimer Disease

By LabMedica International staff writers
Posted on 14 Oct 2021
Print article
Image: Simoa is an ultra-sensitive immunoassay technology that allow detection of proteins and nucleic acids at lowest possible levels (Photo courtesy of Quanterix)
Image: Simoa is an ultra-sensitive immunoassay technology that allow detection of proteins and nucleic acids at lowest possible levels (Photo courtesy of Quanterix)
Blood-based tests for brain amyloid-β (Aβ) pathology are needed for widespread implementation of Alzheimer disease (AD) biomarkers in clinical care and to facilitate patient screening and monitoring of treatment responses in clinical trials.

Reliable measurements of Aβ in blood proved challenging until the development of advanced mass spectrometry and immunodetection methods. Recent articles have suggested that Aβ42/40 quantified using ultrasensitive and fully automated immunoassay platforms could predict Aβ-PET status (especially when combined with APOE genotype) with accuracy approaching that of MS-based Aβ42/40 measures.

An international team led by Clinical Neuroscientists at Lund University (Lund, Sweden) compared the performance of plasma Aβ42/40 measured using eight different Aβ assays when detecting abnormal brain Aβ status in patients with early AD. The study included 182 cognitively unimpaired participants and 104 patients with mild cognitive impairment who were enrolled at three different hospitals in Sweden and underwent Aβ positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) and plasma collection from 2010 to 2014.

Plasma Aβ42/40 was measured using an immunoprecipitation-coupled mass spectrometry developed at Washington University School of Medicine (IP-MS-WashU, St Louis, MO, USA), antibody-free liquid chromatography MS developed by Araclon (LC-MS-Arc, Zaragoza, Spain), and diverse immunoassays. Plasma Aβ42/40 was also measured using an IP-MS–based method from Shimadzu (Kyoto, Japan) in 200 participants (IP-MS-Shim) and an IP-MS–based method from the University of Gothenburg (IP-MS-UGOT, Gothenburg, Sweden) and another immunoassay, the N4PE Simoa immunoassay (IA-Quan, Quanterix Billerica, MA, USA) among 227 participants.

When the team identified participants with abnormal CSF Aβ42/40 in the whole cohort, plasma IP-MS-WashU Aβ42/40 showed significantly higher accuracy than LC-MS-Arc Aβ42/40, and some immunoassays. Plasma IP-MS-WashU Aβ42/40 performed significantly better than IP-MS-UGOT Aβ42/40 and IA-Quan Aβ42/40, while there was no difference in the AUCs between IP-MS-WashU Aβ42/40 and IP-MS-Shim Aβ42/40) in the two sub-cohorts where these biomarkers were available. Plasma IPMS-WashU Aβ42/40 and IP-MS-Shim Aβ42/40 showed highest coefficients for correlations with CSF Aβ42/40.

The authors concluded that the results from two independent cohorts indicate that certain MS-based methods performed better than most of the immunoassays for plasma Aβ42/40 when detecting brain Aβ pathology. The study was published on September 20, 2021 in the journal JAMA Neurology.

Related Links:
Lund University
Washington University School of Medicine
Araclon
University of Gothenburg
Quanterix


Gold Supplier
Molecular Diagnostic System
Singuway 9600 Pro
New
Respiratory Multiplex RT-PCR Kit
Respiratory Multiplex RT-PCR Kit
New
GADAb ELISA Assay
KRONUS Glutamic Acid Decarboxylase Autoantibody (GADAb) ELISA Assay Kit
New
Gold Supplier
TBI Blood Test
i-STAT TBI Plasma Test

Print article

Channels

Molecular Diagnostics

view channel
Image: Absence of nuclear immunohistochemical staining of MSH2 protein (A) and presence of MLH1 protein (B) in urothelial cell carcinoma of the urinary bladder of a patient carrying a germline MSH2 mutation. Observe the nuclear staining in stromal cells as an internal control (Photo courtesy of Radboud University Nijmegen Medical Centre)

Simple Urine Test Detects Urothelial Cancers in Lynch Syndrome Patients

Lynch Syndrome (LS) is an inherited genetic disorder that carries a high risk of cancer. LS is caused by mutations affecting MLH1, MSH2, MSH6 or PMS2 genes. More than one in 300 people have LS but most... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test for screening, diagnosis and management of sickle cell disease and related hemoglobinopathies at the point of care (Photo courtesy of Hemex Health)

Point-of-Care Device Accurately Rapidly Diagnoses Sickle Cell Disease

Hemoglobinopathies are the most common autosomal hereditary disorders. Approximately 7% of the global population carries hemoglobin gene mutation including structural hemoglobin variants like sickle hemoglobin... Read more

Immunology

view channel
Image: The IMMULITE 2000 XPi Immunoassay System provides multiple tests on a single, easy-to-use analyzer, including the thyroid-stimulating immunoglobulin assay (Photo courtesy of Siemens Healthcare)

Immunoassays Evaluated for Thyroid-Stimulating Receptor Antibody in Graves’ Disease

Graves' disease (GD), also known as toxic diffuse goiter, is an autoimmune disease that affects the thyroid. It frequently results in and is the most common cause of hyperthyroidism and it also often results... Read more

Microbiology

view channel
Image: The sciREADER CL2 enables high quality digital colorimetric imaging of various support formats (Photo courtesy of SCIENION)

Multiplex Immunoassay Developed for Confirmation and Typing of HTLV Infections

Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated five to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated... Read more

Pathology

view channel
Illustration

AI Accurately Detects and Diagnoses Colorectal Cancer from Tissue Scans As Well or Better Than Pathologists

Artificial intelligence (A) can accurately detect and diagnose colorectal cancer from tissue scans as well or better than pathologists, according to a new study. The study, which was conducted by researchers... Read more

Technology

view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more

Industry

view channel
Illustration

Global Point of Care Diagnostics Market to Top USD 35 Billion by 2027 Due to Rising Diabetic Cases

The global point of care diagnostics market is projected to grow at a CAGR of close to 6% from more than USD 23 billion in 2020 to over USD 35 billion by 2027, driven by an increase in the number of diabetic... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.